AKRO
Akero Therapeutics, Inc.54.65
+0.00+0%
Dec 9, 9:30:00 AM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.50BP/E (TTM)
-Basic EPS (TTM)
-3.75Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Akero prepays full loan
Akero Therapeutics cleared its $37.6 million debt to Hercules Capital on September 23, 2025, fully prepaying the outstanding Term Loan from a $150 million facility where it had drawn $35 million. This termination ends all obligations under the 2022 Loan Agreement, freeing the biotech from variable interest payments—pegged at the greater of 7.65% or prime plus 3.65%—and monthly principal due post-January 2026. Debt off the books. No further covenants bind the company.
10-Q
Q2 FY2025 results
Akero Therapeutics posted a Q2 net loss of $70.5M, up 26% y/y from $56.0M, driven by R&D expenses climbing to $69.3M from $55.3M as the Phase 3 SYNCHRONY program advances for efruxifermin in MASH patients. The six-month net loss widened to $141.2M from $109.3M y/y, with diluted EPS at -$0.86 for the quarter versus -$0.81, confirmed against 81.7M weighted shares. Cash burn hit $115.9M in operating activities for the half, offset by $399M in financing from a January follow-on offering, leaving $220.4M in cash equivalents and $865.8M in marketable securities at quarter-end, alongside a $35.7M loan payable maturing in 2027. No revenue yet, but liquidity supports trials through at least mid-2026. Clinical delays from enrollment hurdles pose a key risk.
8-K
Akero's Q2 results and MASH data
Akero Therapeutics reported Q2 2025 financials, highlighting $1,086.2 million in cash equivalents to fund operations into 2028, while operating expenses climbed to $80.9 million from $65.7 million year-over-year due to Phase 3 trials. Key updates included NEJM publication of 96-week SYMMETRY data showing EFX's reversal of compensated cirrhosis in MASH patients, reinforced by EASL presentations on anti-fibrotic effects across stages. Phase 3 readouts loom in 2026-2027. Cash burn accelerates, yet data momentum builds.
AGIO
Agios Pharmaceuticals, Inc.
26.09-0.76
AGTX
Agentix Corp.
0.04+0.00
AKTX
Akari Therapeutics Plc
0.25-0.16
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
ETNB
89bio, Inc.
14.84+0.00
FGEN
FibroGen, Inc
9.51-0.53
KROS
Keros Therapeutics, Inc.
21.53+0.30
KRRO
Korro Bio, Inc.
8.22+0.26
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
VKTX
Viking Therapeutics, Inc.
35.72-0.43